Danielle Brill
Stock Analyst at Raymond James
(1.33)
# 2,580
Out of 4,479 analysts
54
Total ratings
37.21%
Success rate
-11.62%
Average return
Main Sectors:
16 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRON Disc Medicine | Maintains: Outperform | $40 → $43 | $46.47 | -7.47% | 5 | May 10, 2024 | |
| ARGX argenx SE | Maintains: Strong Buy | $580 → $520 | $434.22 | +19.75% | 6 | Dec 21, 2023 | |
| BIIB Biogen | Upgrades: Outperform | $283 | $231.77 | +22.10% | 1 | Dec 7, 2023 | |
| PASG Passage Bio | Maintains: Outperform | $9 → $5 | $0.89 | +464.97% | 5 | Nov 14, 2023 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $135 → $145 | $140.11 | +3.49% | 4 | Nov 1, 2023 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $26 → $27 | $30.42 | -11.24% | 6 | Nov 1, 2023 | |
| IMVT Immunovant | Upgrades: Outperform | $40 | $27.51 | +45.40% | 3 | Sep 27, 2023 | |
| PTCT PTC Therapeutics | Downgrades: Underperform | n/a | $31.17 | - | 8 | Sep 18, 2023 | |
| QURE uniQure | Maintains: Outperform | $56 → $50 | $4.45 | +1,024.86% | 4 | Aug 2, 2023 | |
| FGEN FibroGen | Downgrades: Market Perform | n/a | $0.77 | - | 4 | Jun 27, 2023 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | $52 | $37.69 | +37.97% | 1 | Oct 19, 2022 | |
| VRTX Vertex Pharmaceuticals | Initiates: Market Perform | n/a | $471.25 | - | 1 | Jul 1, 2021 | |
| AGIO Agios Pharmaceuticals | Initiates: Market Perform | n/a | $43.38 | - | 1 | Jul 1, 2021 | |
| ACAD ACADIA Pharmaceuticals | Downgrades: Outperform | n/a | $16.04 | - | 2 | Mar 9, 2021 | |
| SRPT Sarepta Therapeutics | Downgrades: Market Perform | n/a | $156.75 | - | 2 | Jan 8, 2021 | |
| SAGE Sage Therapeutics | Initiates: Buy | n/a | $11.03 | - | 1 | May 16, 2017 |
Disc Medicine
May 10, 2024
Maintains: Outperform
Price Target: $40 → $43
Current: $46.47
Upside: -7.47%
argenx SE
Dec 21, 2023
Maintains: Strong Buy
Price Target: $580 → $520
Current: $434.22
Upside: +19.75%
Biogen
Dec 7, 2023
Upgrades: Outperform
Price Target: $283
Current: $231.77
Upside: +22.10%
Passage Bio
Nov 14, 2023
Maintains: Outperform
Price Target: $9 → $5
Current: $0.89
Upside: +464.97%
Neurocrine Biosciences
Nov 1, 2023
Maintains: Outperform
Price Target: $135 → $145
Current: $140.11
Upside: +3.49%
Harmony Biosciences Holdings
Nov 1, 2023
Maintains: Outperform
Price Target: $26 → $27
Current: $30.42
Upside: -11.24%
Immunovant
Sep 27, 2023
Upgrades: Outperform
Price Target: $40
Current: $27.51
Upside: +45.40%
PTC Therapeutics
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $31.17
Upside: -
uniQure
Aug 2, 2023
Maintains: Outperform
Price Target: $56 → $50
Current: $4.45
Upside: +1,024.86%
FibroGen
Jun 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.77
Upside: -
Xenon Pharmaceuticals
Oct 19, 2022
Initiates: Outperform
Price Target: $52
Current: $37.69
Upside: +37.97%
Vertex Pharmaceuticals
Jul 1, 2021
Initiates: Market Perform
Price Target: n/a
Current: $471.25
Upside: -
Agios Pharmaceuticals
Jul 1, 2021
Initiates: Market Perform
Price Target: n/a
Current: $43.38
Upside: -
ACADIA Pharmaceuticals
Mar 9, 2021
Downgrades: Outperform
Price Target: n/a
Current: $16.04
Upside: -
Sarepta Therapeutics
Jan 8, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $156.75
Upside: -
Sage Therapeutics
May 16, 2017
Initiates: Buy
Price Target: n/a
Current: $11.03
Upside: -